Oncology On-The-Go Podcast: COVID-19 Vaccination and Cellular Therapy in Cancer

Podcast

Fareed Khawaja, MBBS, and Marilyne Daher, MD discuss COVID-19 vaccine efficacy and safety among patients with cancer in the United States.

Fareed Khawaja, MBBS, assistant professor in the Department of Infectious Diseases, Infection Control, and Employee Health at The University of Texas MD Anderson Cancer Center, and Marilyne Daher, MD, medical resident in the Department of Internal Medicine at Baylor College of Medicine, spoke with CancerNetwork® about their study titled COVID-19 Vaccination in Patients with Cancer and Recipients of Cellular Therapy, which was published in the journal ONCOLOGY®.

In their study, Khawaja and Daher gave an overview of the current COVID-19 vaccines that are available in the United States, published data on vaccine efficacy and safety in patients with cancer, current vaccination guidelines, and future strategies for preventing COVID-19–related complications.

Don’t forget to subscribe to the “Oncology On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Recent Videos
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Earlier and more frequent talks about disabling ICDs with patients receiving end-of-life care and their families may help avoid excessive pain.
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
AI-powered tools may help alleviate doctor burnout and give clinicians more time to directly engage with patients.
Artificial intelligence may have the potential to enrich pathology practices to help identify aspects of tumor biology not seen with the human eye.
Efficacy results from the MASAI trial preceded the creation of the UK-funded EDITH trial, assessing 5 AI platforms in 700,000 women undergoing mammography.
Related Content
The Potential for Improved Processes, Outcomes, and Economics of Health Care

The Potential for Improved Processes, Outcomes, and Economics of Health Care

Nora Janjan, MD, MPSA, MBA
February 21st 2025
Article

DOGE hopes to solve rampant inefficiencies in US healthcare that contribute to unsustainable costs and a broken system by cutting spending and administrative waste.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
February 10th 2025
Podcast

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Forecast on Eliminating Cancer Disparities Looks to Ethnic Enclave Research

Forecast on Eliminating Cancer Disparities Looks to Ethnic Enclave Research

Ariana Pelosci
February 18th 2025
Article

Scarlett Lin Gomez, MPH, PhD, highlights facts from her research that are impacting cancer disparities and how she is finding ways to improve them.

Expanding and Advancing the Future of Renal Cell Carcinoma Treatment

Expanding and Advancing the Future of Renal Cell Carcinoma Treatment

Eric Jonasch, MD
February 3rd 2025
Podcast

Eric Jonasch, MD, believes that the Kidney Cancer Research Consortium may broaden their reach to provide care to many different groups of patients.

FDA Approves Vimseltinib in Tenosynovial Giant Cell Tumor

FDA Approves Vimseltinib in Tenosynovial Giant Cell Tumor

Tim Cortese
February 14th 2025
Article

Vimseltinib elicited an ORR of 40% vs 0% of matching placebo in patients with tenosynovial giant cell tumor in the phase 3 MOTION trial.

The decision impacts the phase 1 STARLING trial and additional phase 1 trials sponsored by the Moffitt Cancer Center evaluating TIDAL-01 in solid tumors.

Program Evaluating TIDAL-01 in Solid Tumors Has Been Discontinued

Roman Fabbricatore
February 7th 2025
Article

The decision impacts the phase 1 STARLING trial and additional phase 1 trials sponsored by the Moffitt Cancer Center evaluating TIDAL-01 in solid tumors.